Hiraide Sakura, Ono Sadahide, Kato Satoshi
Department of Clinical Oncology, Iwate Prefectural Central Hospital, Morioka, Japan.
Department of Pathology, Iwate Prefectural Central Hospital, Morioka, Japan.
Case Rep Oncol. 2017 May 8;10(2):420-427. doi: 10.1159/000475463. eCollection 2017 May-Aug.
Metastatic neuroendocrine tumors (gastrinomas) have a poor prognosis. Octreotide can reduce gastrin levels and alleviate hormonal symptoms, and possibly slow tumor growth as well. No drugs were available except streptozocin for the treatment of metastatic pancreatic neuroendocrine tumor (PNET) in 2008. We report a case of PNET in a 53-year-old woman with multiple liver tumors treated with S-1 plus octreotide. After 6 months from the initiation of the treatment, the pancreatic tumor and liver metastases regressed, and the patient achieved partial response without the development of any serious adverse event. For more than 8 years, the patient has remained asymptomatic without disease progression and is continuing treatment with octreotide and S-1. A marked suppression of gastrin levels has also been achieved. Combination therapy with octreotide and S-1 has been effective and well tolerated in patients with metastatic gastrinoma.
转移性神经内分泌肿瘤（胃泌素瘤）预后较差。奥曲肽可降低胃泌素水平、缓解激素症状，也可能减缓肿瘤生长。2008年时，除链脲霉素外，尚无其他药物可用于治疗转移性胰腺神经内分泌肿瘤（PNET）。我们报告1例53岁患有多发肝肿瘤的女性PNET患者，接受S-1加奥曲肽治疗。治疗开始6个月后，胰腺肿瘤和肝转移灶缩小，患者获得部分缓解，且未发生任何严重不良事件。8年多来，患者一直无症状，病情无进展，目前仍在接受奥曲肽和S-1治疗。胃泌素水平也得到了显著抑制。奥曲肽和S-1联合治疗对转移性胃泌素瘤患者有效且耐受性良好。
